【品大事】 仙鹤股份：拟110亿元投建林浆纸用一体化高性能纸基新材料项目 仙鹤股份公告，公司拟投资约110亿元建设林浆纸用一体化高性能纸基新材料项目，其中一期投资约55 亿元，二期投资约55亿元，正式动工之日起计三年内实现一期投产。一期项目计划投资约55亿元，预计 年产值约51.5亿元，年税收约4.5亿元，提供就业岗位约2000人。二期项目将根据一期项目的实施情况， 参照市场形势和企业经营情况，适时投资建设。 8月6日晚间，沪深两市多家上市公司发布公告，以下是第一财经对一些重要公告的汇总，供投资者参 考。 中信证券公告，公司控股子公司华夏基金2025年上半年实现营业收入42.58亿元，净利润11.23亿元，综 合收益总额11.06亿元。截至2025年6月30日，华夏基金母公司管理资产规模为28512.37亿元。上述数据 为初步核算数据，未经会计师事务所审计，具体数据以公司2025年半年度报告中披露的数据为准。 百济神州：上半年净利润4.5亿元 同比扭亏为盈 百济神州公告，2025年半年度公司产品收入为173.60亿元，较上年同比上升45.8%；营业总收入175.18 亿元，较上年同比上升46.0%；归属于母公 ...

皓元医药公告，股东苏民投君信（上海）产业升级与科技创新股权投资合伙企业（有限合伙）持股 690.94万股，占3.26%；因资金需求，拟于2025年8月29日～2025年11月28日，通过集中竞价减持不超过 212.1万股，占1%，通过大宗交易减持不超过424.2万股，占2%，合计减持不超636.3万股，占3.00%。 ...

Group 1: Aojie Technology - Aojie Technology has made significant progress in ASIC business, RedCap chips, and 4G/5G smartphone chips [1] - The ASIC business is focused on smart wearables, edge SOC, RISC-V, and cloud inference chips, with expected substantial revenue growth by 2026 [1] - RedCap chips are commercially available in the IoT market, and the company has production capabilities in the smart wearable market [1] - The company has successfully commercialized 4G quad-core chips and is making steady progress in the development of 4G octa-core, 6nm 4G octa-core, and 6nm 5G octa-core chips [1] - Aojie Technology plans to control the growth of operating and R&D expenses to no more than 15% and has no plans for convertible bond issuance or Hong Kong listing [1] Group 2: Haoyuan Pharmaceutical - Haoyuan Pharmaceutical is committed to a global development strategy, with international business revenue expected to account for nearly 40% in 2024 [1] - The company has established collaborations with multinational pharmaceutical giants, universities, research institutes, and CROs [1] - The net operating cash flow is projected to turn positive to 380 million yuan in 2024, with continued focus on cash flow management in 2025 [1] - The company has a strong presence in the ADC field, with the Chongqing ADC CDMO factory providing one-stop services [1] - Haoyuan Pharmaceutical emphasizes ESG practices, having established an ESG governance framework and received multiple ESG awards [1] Group 3: Chongda Technology - Chongda Technology anticipates positive growth in the global PCB market by 2025, with strong order demand and rising product prices [2] - The company's capacity utilization rate is at 85%, with new production capacities being added in Zhuhai and Thailand [2] - To improve profitability, Chongda Technology is focusing on high-value customers, optimizing sales structure, and enhancing cost management [2] - The company is implementing a structural price increase strategy to address rising raw material costs [2] - The U.S. market accounts for 10% of the company's revenue, and it is adopting strategies to diversify markets and optimize customer cooperation in response to tariff policy changes [2]

Core Points - The company announced the results of the second vesting period for its 2023 restricted stock incentive plan, with 527,660 shares to be listed on August 6, 2025, representing 0.25% of the company's total share capital before vesting [2][3][4] Group 1: Stock Incentive Plan Details - The stock listing type is for equity incentive shares, with a total of 527,660 shares to be listed [2][3] - The decision-making process for the stock vesting was approved by the board and supervisory committee on June 26, 2023, and the plan was publicly disclosed on June 27, 2023 [4][5][6] - The number of individuals eligible for the stock vesting is 97, with the actual number of shares vesting being 527,660 [12][13] Group 2: Stock Listing and Capital Changes - The listing date for the vested shares is set for August 6, 2025, and the total share capital will increase from 211,571,033 shares to 212,098,693 shares [14][17] - The company received a total of RMB 11,904,009.60 from the 97 participants in the stock incentive plan, which includes an increase in share capital of RMB 527,660 [17] - The impact of the new shares on the company's financial report is minimal, with the diluted earnings per share remaining stable [18] Group 3: Convertible Bond Adjustments - The company announced an adjustment to the conversion price of its convertible bonds ("Hao Yuan Convertible Bonds") due to the completion of the stock vesting [19][20] - The conversion price was adjusted from RMB 40.59 to RMB 40.55 per share, effective from August 5, 2025 [23][26] - The adjustment was made in accordance with the company's regulations and relevant laws, ensuring the protection of bondholders' rights [24][25]

Core Viewpoint - The announcement details the results of the second vesting period of the 2023 restricted stock incentive plan for Shanghai Haoyuan Pharmaceutical Co., Ltd, including the number of shares to be listed and the relevant procedures for vesting and stock issuance [1][2][3]. Group 1: Stock Listing and Vesting Details - The total number of shares to be listed for trading is 527,660 shares, with the listing date set for August 6, 2025 [1][12]. - The second vesting period for the restricted stock was completed on July 31, 2025, and the company has received the necessary registration proof from the Shanghai branch of China Securities Depository and Clearing Corporation [1][11]. - The total number of shares vested in this period is 52.7660 million shares, which represents 50% of the total granted shares [8]. Group 2: Decision-Making Process - The decision-making process for the vesting involved multiple meetings, including the board of directors and the supervisory board, which approved the relevant proposals regarding the incentive plan [2][4]. - The independent directors provided their consent to the proposals related to the 2023 incentive plan [2][4]. - The company conducted an internal public notice regarding the list of proposed incentive recipients, with no objections received during the notice period [3]. Group 3: Financial Impact and Share Capital Changes - Following the vesting, the total share capital of the company increased from 211,571,033 shares to 212,098,693 shares [9][11]. - The company reported a net profit attributable to shareholders of 62,384,400.02 yuan for the first quarter of 2025, with basic earnings per share of 0.30 yuan per share [11]. - The new shares will dilute the earnings per share based on the increased total share capital while keeping the net profit unchanged [11].

| 证券代码：688131 | 证券简称：皓元医药 | 公告编号：2025-097 | | --- | --- | --- | | 转债代码：118051 | 转债简称：皓元转债 | | 上海皓元医药股份有限公司 关于 2023 年限制性股票激励计划第二类限制性股票 第二个归属期归属结果暨股份上市公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为股权激励股份；股票认购方式为网下，上市股数为 527,660股。占归属前公司股本总额的 0.25%。 本次股票上市流通总数为527,660股。 本次股票上市流通日期为2025 年 8 月 6 日。 根据中国证监会、上海证券交易所、中国证券登记结算有限责任公司上海分 公司有关业务规则的规定，上海皓元医药股份有限公司（以下简称"公司"）2023 年限制性股票激励计划第二类限制性股票第二个归属期于 2025 年 7 月 31 日完成 归属登记手续，已收到中国证券登记结算有限责任公司上海分公司出具的《证券 变更登记证明》。现将有关情况公告如下： 一、本 ...

| 证券代码：688131 | 证券简称：皓元医药 | 公告编号：2025-098 | | --- | --- | --- | | 转债代码：118051 | 转债简称：皓元转债 | | 上海皓元医药股份有限公司 关于调整可转换公司债券"皓元转债"转股价格暨 转股停复牌的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券停复牌情况：适用 因公司 2023 年限制性股票激励计划第二类限制性股票完成归属导致"皓元转 债"转股价格调整,本公司的相关证券停复牌情况如下： | | 证券简称 | 停复牌类型 | 停牌起始日 | 停牌 期间 | 停牌终止日 | 复牌日 | | --- | --- | --- | --- | --- | --- | --- | | | 皓元转债 | 可转债转股停 牌 | 2025/8/4 | 全天 | 2025/8/4 | 2025/8/5 | | 证券代码 118051 | | | | | | | 经中国证券监督管理委员会《关于同意上海皓元医药股份有限公司向不特定 对象发行可转换公司 ...

证券之星消息，7月30日医疗服务板块较上一交易日下跌1.45%，皓元医药领跌。当日上证指数报收于 3615.72，上涨0.17%。深证成指报收于11203.03，下跌0.77%。医疗服务板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 301096 | 百诚医药 | 54.58 | 7.65% | 11.38万 | | 6.09亿 | | 688710 | 益诺思 | 46.53 | 3.86% | 5.10万 | | 2.36亿 | | 300683 | 海特生物 | 51.98 | 2.71% | 17.99万 | | 8.88亿 | | 600721 | 自化医药 | 8.48 | 2.17% | 48.33万 | | 4.09亿 | | 300404 | 博济医药 | 11.20 | 1.17% | 47.49万 | | 5.34亿 | | 300149 | 睿智医药 | 13.75 | 1.03% | 163.19万 | | 23.44亿 | | 0 ...

CRO概念板块短线走低，皓元医药跌超10%，药石科技、海特生物、昭衍新药、凯莱英等跟跌。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688131 证券简称：皓元医药 公告编号：2025-096 转债代码：118051 转债简称：皓元转债 上海皓元医药股份有限公司关于不提前赎回"皓元转债"的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （三）可转债转股期限 根据有关规定和《募集说明书》的约定，公司本次发行的"皓元转债"自2025年6月4日起可转换为公司股 票。转股期间为2025年6月4日至2030年11月27日，初始转股价格为40.73元/股。 （四）可转债转股价格的历次调整情况 ● 自2025年7月8日至2025年7月29日期间，上海皓元医药股份有限公司（以下简称"公司"或"皓元医 药"）股票满足在连续三十个交易日中有十五个交易日的收盘价不低于"皓元转债"当期转股价格（40.59 元/股）的130%（含130%，即52.77元/股），已触发《上海皓元医药股份有限公司向不特定对象发行可 转换公司债券募集说明书》（以下简称"《募集说明书》"）中规定的有条件赎回条款。 ● 公 ...